WINTON GROUP Ltd Acquires New Holdings in Vertex Pharmaceuticals Incorporated $VRTX

Posted by Francis Steltz on Jun 7th, 2026

WINTON GROUP Ltd acquired a new stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 10,623 shares of the pharmaceutical company’s stock, valued at approximately $4,816,000.

A number of other large investors have also recently added to or reduced their stakes in VRTX. Colonial Trust Co SC grew its stake in Vertex Pharmaceuticals by 118.8% in the 3rd quarter. Colonial Trust Co SC now owns 70 shares of the pharmaceutical company’s stock valued at $27,000 after acquiring an additional 38 shares during the last quarter. Eagle Bay Advisors LLC acquired a new stake in Vertex Pharmaceuticals in the 4th quarter valued at about $29,000. IMG Wealth Management Inc. grew its stake in Vertex Pharmaceuticals by 277.8% in the 4th quarter. IMG Wealth Management Inc. now owns 68 shares of the pharmaceutical company’s stock valued at $31,000 after acquiring an additional 50 shares during the last quarter. Ares Financial Consulting LLC acquired a new stake in shares of Vertex Pharmaceuticals during the 4th quarter worth about $33,000. Finally, Archer Investment Corp boosted its stake in shares of Vertex Pharmaceuticals by 89.7% during the 4th quarter. Archer Investment Corp now owns 74 shares of the pharmaceutical company’s stock worth $34,000 after purchasing an additional 35 shares during the last quarter. 90.96% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

VRTX has been the topic of several analyst reports. Scotiabank raised their price target on shares of Vertex Pharmaceuticals from $495.00 to $558.00 and gave the stock an “outperform” rating in a research note on Friday, February 13th. Bank of America raised their price target on shares of Vertex Pharmaceuticals from $571.00 to $598.00 and gave the stock a “buy” rating in a research note on Tuesday, March 10th. HC Wainwright raised their price target on shares of Vertex Pharmaceuticals from $591.00 to $641.00 and gave the stock a “buy” rating in a research note on Tuesday, March 10th. Stifel Nicolaus raised their price target on shares of Vertex Pharmaceuticals from $445.00 to $466.00 and gave the stock a “hold” rating in a research note on Friday, February 13th. Finally, Truist Financial initiated coverage on shares of Vertex Pharmaceuticals in a research note on Wednesday, May 27th. They set a “buy” rating and a $542.00 price target on the stock. Twenty-two equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $555.91.

Get Our Latest Stock Report on VRTX

Vertex Pharmaceuticals Trading Up 1.2%

NASDAQ VRTX opened at $446.83 on Friday. The company’s fifty day simple moving average is $437.33 and its 200-day simple moving average is $451.81. Vertex Pharmaceuticals Incorporated has a 52 week low of $362.50 and a 52 week high of $507.92. The stock has a market cap of $113.41 billion, a P/E ratio of 26.50, a PEG ratio of 1.91 and a beta of 0.30.

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) last posted its earnings results on Monday, May 4th. The pharmaceutical company reported $4.47 EPS for the quarter, topping analysts’ consensus estimates of $4.24 by $0.23. Vertex Pharmaceuticals had a net margin of 35.51% and a return on equity of 23.86%. The business had revenue of $2.99 billion for the quarter, compared to analysts’ expectations of $2.99 billion. During the same period in the previous year, the company posted $4.06 earnings per share. The business’s revenue for the quarter was up 8.3% compared to the same quarter last year. On average, research analysts expect that Vertex Pharmaceuticals Incorporated will post 17.02 EPS for the current fiscal year.

Insider Transactions at Vertex Pharmaceuticals

In other news, Director Sangeeta N. Bhatia sold 318 shares of the business’s stock in a transaction on Monday, May 4th. The shares were sold at an average price of $423.73, for a total transaction of $134,746.14. Following the transaction, the director directly owned 4,924 shares of the company’s stock, valued at approximately $2,086,446.52. The trade was a 6.07% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CMO Carmen Bozic sold 6,988 shares of the business’s stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $450.00, for a total transaction of $3,144,600.00. Following the transaction, the chief marketing officer directly owned 26,088 shares in the company, valued at approximately $11,739,600. The trade was a 21.13% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 11,717 shares of company stock valued at $5,309,945. Corporate insiders own 0.20% of the company’s stock.

About Vertex Pharmaceuticals

(Free Report)

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.